Site-specific delivery of colchicine in rat carotid artery model of restenosis

Journal of Controlled Release

Volumn 45, Issue 1, 1997, Pages 65-73

  Mishaly, David ^a,b   Fishbein, Ilia ^b   Moscovitz, Dorit ^b   Golomb, Gershon ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Colchicine; Controlled release; Implantable drug delivery system; Intimal hyperplasia; Restenosis

Indexed keywords

COLCHICINE; ETHYLENE VINYL ACETATE COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION;

EID: 0031015567     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01546-5     Document Type: Article

References (43)

1. J.J. Pompa, R.M. Califf and EJ. Topol, Clinical trials of restenosis after coronary angioplasty. Circulation 84 (1991) 1426-1436.
2. M. Ferrell, V. Fuster, H.K. Gold and J.H. Chesebro, A dilemma for the 1990s: choosing appropriate experimental animal model for the prevention of restenosis. Circulation 85 (1992) 1630-1631.
3. P.W. Serruys, D.P. Foley and P.J. de Feyter, Restenosis after coronary angioplasty: a proposal of new comparative approaches based on quantitative angioplasty. Br. Heart J. 68 (1992) 417-424.
4. R. Ross, The pathiogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809.
5. T. Kakuta, J.W. Currier, C.C. Haudenchild, T.J. Ryan and D.P. Faxon, Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 89 (1994) 2809-2815.
6. S.D. Gertz, L.W. Gimple, S. Banai, M. Ragosta, E.R. Powers, W.C. Roberts, L.S. Ferez and I.J. Sarembock, Geometric remodeling is not the principal pathogenic process in restenosis after balloon angioplasty. Circulation 90 (1994) 3001-3008.
7. V. Fuster, E. Falk, J.T. Fallon, L. Badimon, J.H. Chesebro and J. J. Badimon, The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb. Haemost. 74 (1995) 552-559.
8. D.V.M. Muller, S.G. Ellis and E.J. Topol, Colchicine and antineooplastic therapy for the prevention of restenosis following percutaneous coronary interventions. J. Am. Coll. Cardiol. 17 Suppl. B (1991) 126B-131B.
9. R.S. Schwartz, D.R.J. Holmes and E.J. Topol, The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20 (1992) 1284-1293.
10. J.-P.R. Herrman, W.R.M. Hermans, J. Vos and P.W. Serruys, Pharmacological approaches to the prevention of restenosis following angioplasty: part I. Drugs 46 (1993) 18-52.
11. A.W. Clowes and S.M. Schwartz, Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ. Res. 56 (1985) 139-145.
12. T. Ohara, S. NAnto, S. Assada, K. Komamura and D. Wang, Ultrastructural study of proliferating and migrating smooth muscle cells at the site of PTCA as an explanation for restenosis. Circulation 78 Suppl. II (1988) II-290.
13. J.H. Campbell and G.R. Campbell, Chemical stimuli of the hypertrophie response to smooth muscle. In: C.L. Seidel (Eds.) Hypertrophie Response of Smooth Muscle, CRC Press, Boca Raton, FL, 1987, pp. 153-192.
14. P. Libby, S.J.C. Warner, R.N. Salomon and L.K. Birinyl, Production of platelet-derived growth factor-like mitogen by smooth muscle cells from human atheroma. N. Engl. J. Med. 318 (1988) 1493-1498.
15. A. Jawien, D.F. Bowen-Pope, V. Linder, S.M. Schwartz and A.W. Clowes, Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. (1992) 507-511.
16. E.R. Edelman, M.A. Nugent, L.T. Smith and M.J. Karnovsky, Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proiferation of vasa vasorum in injured rat arteries. J. Clin. Invest. 89 (1992) 465-473.
17. T. Okada, D.H. Bark and M.R. Mayberg, Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. Neurosurgery 25 (1989) 892-898.
18. M. Simons, E.R. Edelamn and R.D. Rosenberg, Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 93 (1994) 2351-2356.
19. A.E. Villa, L.A. Guzman, W. Chen, G. Golomb, R.J. Levy and E.J. Topol, Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J. Clin. Invest. 93 (1994) 1243-1249.
20. G. Golomb, R. Mayberg and A.J. Domb, Perivascular drug delivery. In: A.J. Domb (Eds.) Polymer Site-specific Pharmacotherapy, John Wiley and Sons, NY, 1994, pp. 206-219.
21. G. Golomb, D. Moskovitz, I. Fishbein and D. Mishaly, Perivascular polymeric controlled-release therapy. In: D.L. Wise (Eds.) Encyclopedic Handbook of Biomaterials and Bioengineering, Marcel Dekker, NY, 1995, pp. 1043-1055.
22. W. Hollander, D.M. Kramsch, C. Franzblau, J. Paddock and M.A. Colombo, Suppression of ahteromatous fibrous plaque formation by antiproliferative and anti-inflammatory drugs. Circ. Res. 34 Suppl. I (1974) I-131-140.
23. W. Hollander, J. Paddock, S. Nagrat, M. Colombo and B. Kirkpatraick, Effects of anticalcifying and antifibrotic drugs on pre-established atherosclerosis in the rabbit. Atherosclerosis 33 (1979) 111-123.
24. G. Godeau, G. Lagrue, J. Wegrowski et al., Effect of colchicine on atherosclerosis. Clin. Physiol. Biochem. 3 (1985) 221-239.
25. K. Tanaka, M. Honda, T. Kuramochi and S. Morioka, Prominent inhibitory effects of tranilat on migration and proliferation and collagen synthesis by vascular smooth muscle cells. Atherosclerosis 107(2) (1994) 179-185.
26. K.L. March, S. Mohanraj, P. Ho, R.L. Wilensky and D.R. Hathaway, Biodegradable microspheres containing a colchicine analogue inhibit DNA synthesis in vascular smooth muscle cells. Circulation 89(5) (1994) 1929-1933.
27. J.H. O'Keefe, B.D. McCallister, T.M. Bateman, D. Kuhnlein, R.W. Ligon and G.O. Hartzler, Colchicine for the prevention of restenosis after coronary angioplasty. J. Am. Coll. Cardiol. 17 (1991) 181A.
28. I. Gradus-Pizlo, R.L. Wilensky, K.L. March, N. Finberg, M. Michaels, G.E. Sandusky and D.R. Hathaway, Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery. J. Am. Coll. Cardiol. 26 (1995) 1549-1557.
29. G. Golomb, R. Langer, F.J. Schoen, S.M. Smith, Y. Choi and R.J. Levy, Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: dose-response and mechanistic studies. J. Controlled Release 4 (1986) 181-194.
30. 3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharm. Res. 9 (1992) 1018-1023.
31. A.W. Clowes, M.A. Reidy and M.M. Clowes, Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab. Invest. 49 (1983).
32. F.D. Malkinson, Colchicine: new uses of an old, old drug. Arch. Dermatol. 118 (1982) 453-457.
33. M. Ehrenfeld, M. Levy and M. Bar Eli, Effect of colchicine on polymorphonuclear leucocyte chemotaxis in human volunteers. Br. J. Clin. Pharmacol. 10 (1980) 297-300.
34. B. Zakhireh and H.L. Malech, The effect of colchicine and vinblastine on the chemotactic response of human monocytes. J. Immunol. 125 (1980) 2143-2153.
35. R.F. Siegelmann and B. Peterkofsky, Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc. Natl. Acad. Sci. USA 69 (1972) 892-896.
36. E.D. Harris Jr. and S.M. Krane, Effects of colchicine on collagenase in cultures of rheumatoid synovium. Arthritis Rheum. 14 (1971) 669-684.
37. D. Menche, A. Israel and S. Karpatkin, Platelet and microtubules: effect of colchicine and D20 on platelet aggregation and release induced by calcium ionophore A23187. J. Clin. Invest. 66 (1980) 284-291.
38. J.W. Currier, T.K. Pow, A.C. Minihan, C.C. Haudenschild, D.P. Faxon and T.J. Ryan, Colchicine inhibits restenosis after coronary angioplasty. Circulation 80 Suppl. II (1989) II-66.
39. E.R. Edelman, D.H. Adams and M.J. Karnovsky, Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. USA 87 (1990) 3773-3777.
40. M. Simons, E.R. Edelman, J.-L. DeKeyser, R. Langer and R.D. Rosenberg, Antisense c-myb oligonucleotides inhibit intimal smooth muscle cell accumulation in vivo. Nature 359 (1992) 67-70.
41. G.K. McEvay (Ed.), Colchicine. In: American Hospital Formulary Service (AHFS) Drug Information, American Society of Health-System Pharmacists, Bethesda, MD, 1994, pp. 2715-2717.
42. E.R. Edelman and M.J. Karnovsky, Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 89 (1994) 770-776.
43. D.W.M. Muller, G. Golomb, D. Gordon and R.J. Levy, Site-specific dexamethasone delivery for the prevention of neointimalthickening after vascular stent implantation. Coron. Artery Dis. 5 (1994) 435-442.